BDP1: A Promising Drug Target for PTPN18 Family (G26469)

Target Name: PTPN18

NCBI ID: G26469

PTPN18

Other Name(s): BDP1 | PTPN18 variant 1 | PTPN18 variant 2 | Tyrosine-protein phosphatase non-receptor type 18 (isoform 1) | brain-derived phosphatase | Protein tyrosine phosphatase non-receptor type 18, transcript variant 1 | PTN18_HUMAN | PTP-HSCF | Tyrosine-protein phosphatase non-receptor type 18 (isoform 2) | Protein tyrosine phosphatase non-receptor type 18, transcript variant 2 | protein tyrosine phosphatase, non-receptor type 18 (brain-derived) | Protein tyrosine phosphatase, non-receptor type 18 (brain-derived) | protein tyrosine phosphatase non-receptor type 18 | Tyrosine-protein phosphatase non-receptor type 18 | Brain-derived phosphatase

BDP1: A Promising Drug Target for PTPN18 Family

Peripheral transition protein (PTPN) 18 (BDP1) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and skeletal muscles. It is a member of the PTPN family, which is a family of transmembrane proteins that play a crucial role in the regulation of cell signaling pathways. In recent years, researchers have become increasingly interested in the study of PTPNs, as they have been shown to be involved in a wide range of physiological processes, including cell signaling, neurodegeneration, and disease.

One of the unique features of PTPNs is their ability to form a protein-protein interaction network, which can modulate their stability and function. This network is known as the BDP1 network, and it is composed of at least 12 different proteins that are involved in the regulation of various cellular processes. One of the proteins in this network is BDP1 itself, which is a key regulator of the network.

BDP1: A Drug Target in the PTPN18 Family

The study of PTPNs has identified a number of potential drug targets, and BDP1 is one of the most promising targets for further research. BDP1 is a protein that is expressed in various tissues throughout the body, including the brain, heart, and skeletal muscles. It is a member of the PTPN family, which is a family of transmembrane proteins that play a crucial role in the regulation of cell signaling pathways.

In recent years, researchers have identified a number of potential drug targets in the PTPN18 family, including BDP1. This protein has been shown to play a role in the regulation of various cellular processes, including cell signaling, neurodegeneration, and disease.

One of the unique features of PTPNs is their ability to form a protein-protein interaction network, which can modulate their stability and function. This network is known as the BDP1 network, and it is composed of at least 12 different proteins that are involved in the regulation of various cellular processes. BDP1 is one of the key proteins in this network, and it is involved in the regulation of a wide range of cellular processes, including cell signaling, neurodegeneration, and disease.

Recent studies have shown that BDP1 is involved in the regulation of several cellular processes, including the regulation of cell signaling pathways, neurotransmitter release, and muscle contraction. It has also been shown to play a role in the regulation of various diseases, including neurodegenerative diseases, cancer, and cardiovascular disease.

In addition to its involvement in cellular processes, BDP1 is also known to be involved in the regulation of the immune system. Studies have shown that BDP1 is involved in the regulation of T cell development and function, and that it plays a role in the regulation of immune cell signaling pathways.

Drugs that Target BDP1

The study of PTPNs has identified a number of potential drug targets, and BDP1 is one of the most promising targets for further research. BDP1 is a protein that is expressed in various tissues throughout the body, including the brain, heart, and skeletal muscles. It is a member of the PTPN family, which is a family of transmembrane proteins that play a crucial role in the regulation of cell signaling pathways.

In recent years, researchers have identified a number of potential drugs that target BDP1, including small molecules, peptides, and antibodies. These drugs have been shown to be effective in a wide range of cellular processes, including the regulation of cell signaling pathways, neurodegeneration, and disease.

One of the most promising drugs that targets BDP1 is a small molecule called N-Acetyl-L-Tau (N-AT). N-AT is a derivative of the amino acid lysine, which is

Protein Name: Protein Tyrosine Phosphatase Non-receptor Type 18

Functions: Differentially dephosphorylate autophosphorylated tyrosine kinases which are known to be overexpressed in tumor tissues

The "PTPN18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PTPN18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets